EMA approves Fingolimod for RRMS

E

European Commission approves Fingolimod, the first oral multiple sclerosis treatment for use in the EU.
(1) Fingolimod is approved in the EU for people with highly active relapsing-remitting multiple sclerosis (RRMS) despite treatment with beta interferon, or in patients with rapidly evolving severe RRMS. (2) Fingolimod showed superior efficacy to interferon beta-1a IM, a commonly prescribed treatment, reducing relapses by 52% (p<0.001) at one year. (3) Two-year, placebo-controlled study demonstrated that Fingolimod significantly reduced the risk of disability progression. Click here to see a YouTube clip of Fingolimod’s mode of action

About the author

Prof G

Professor of Neurology, Barts & The London. MS & Preventive Neurology thinker, blogger, runner, vegetable gardener, husband, father, cook and wine & food lover.

Add comment

By Prof G

Translate

Categories

Recent Posts

Recent Comments

Archives